Quarterly ResultMay 13, 2026, 07:07 AM
Immunic Raises $200M in Private Placement; Q1 Net Loss $32.6M
AI Summary
Immunic, Inc. reported a Q1 2026 net loss of $32.6 million, or $1.08 per share, compared to a net loss of $25.5 million, or $2.51 per share, in Q1 2025. The company significantly strengthened its financial position by closing an oversubscribed private placement, raising $200 million upfront with the potential for an additional $200 million, extending its cash runway into late 2027. Immunic also announced key leadership appointments, including a new Chief Medical Officer, and expects top-line data from its Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis by the end of 2026.
Key Highlights
- Secured $200 million upfront in an oversubscribed private placement, with potential for $200 million more.
- Reported Q1 2026 net loss of $32.6 million, or $1.08 per share, compared to $25.5 million, or $2.51 per share, in Q1 2025.
- Cash and cash equivalents totaled $186.6 million as of March 31, 2026, extending operations into late 2027.
- Appointed Michael A. Panzara as Chief Medical Officer and Jon Congleton to the Board of Directors.
- Anticipates top-line data from Phase 3 ENSURE trials for vidofludimus calcium in RMS by end of 2026.
- Effected a 1-for-10 reverse stock split and regained Nasdaq minimum bid price compliance.
- Granted a key European patent for vidofludimus calcium, providing protection into 2038.